SCHEMBL16985239

SCHEMBL16985239

O=C(CNS(=O)(=O)c1cc2ccccc2o1)NCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MAOB P27338 1/20 0.51
KMT2A Q03164 4/20 0.50
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46
CCR2 P41597 4/20 0.45
MMP2 P08253 1/20 0.44
MMP14 P50281 1/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA4 P22748 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
POLB P06746 2/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926052 0.83 MMP2 (0.56) ALDH1A1TP53HPGDSMN1; SMN2KMT2A
SCHEMBL4846244 0.75 MMP2 (0.46) ALDH1A1CCR2MMP2MMP14CA2
SCHEMBL21892207 0.74 SMN1; SMN2 (0.56) ALDH1A1TP53HPGDSMN1; SMN2MAOB
SCHEMBL1924635 0.72 CCR2 (0.46) KMT2ACCR2CA2MEN1BCAT1
SCHEMBL19476629 0.72 TP53 (1.00) ALDH1A1TP53HPGDSMN1; SMN2MAOB
SCHEMBL5313231 0.71 KDM4E (0.61) ALDH1A1HPGDKMT2ACA2CA12
SCHEMBL8232257 0.71 CA2 (0.61) HPGDCCR2CA2BCAT1
SCHEMBL20539090 0.70 CCR2 (0.49) MAOBCCR2CA2BCAT1
SCHEMBL28216033 0.70 MMP13 (0.49) ALDH1A1HPGDCCR2CA2KDM4E
SCHEMBL10534704 0.69 CA2 (0.58) TP53SMN1; SMN2MAOBKMT2ACCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 US disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed
WO-2015115507-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME 味の素株式会社 2015-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 ALDH1A1 546/4885TP53 1899/4885HPGD 853/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 ALDH1A1 546/4885TP53 1899/4885HPGD 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.